Compare ADMA Biologics Inc (ADMA) vs Modine Manufacturing Company (MOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Modine Manufacturing Company — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.18B), while Modine Manufacturing Company trades at $198.81 (market cap $10.15B). The key difference: Modine Manufacturing Company is far larger — about 4.7× ADMA Biologics Inc's market cap, and Modine Manufacturing Company is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | MOD | |
|---|---|---|
Market Cap | $2.18B | $10.15B |
Sector | Health | Technology |
52-Week High | $20.38 | $306.89 |
52-Week Low | $7.60 | $119.68 |
Enterprise Value | $2.25B | $10.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Modine Manufacturing (MOD) trades at $195.60, up 1.6% on the day, with a bearish technical signal but strong fundamental growth driven by data center demand. The stock shows stretched valuation with a P/E of 71.27, yet has beaten earnings estimates for three consecutive quarters. Recent news highlights surging data center sales but also margin pressure and supply-chain constraints.
Outlook is mixed: robust revenue growth and a $319 consensus price target suggest upside, but high valuation, margin compression, and technical weakness pose risks. Investors should weigh strong analyst buy ratings against execution challenges in a competitive thermal management market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →
